Metastatic Breast Cancer - Pipeline Review, H1 2016

  • ID: 3774219
  • Report
  • 1079 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Biocon Limited
  • Ensol Biosciences Inc.
  • Immunomedics, Inc.
  • Merck KGaA
  • Oncolytics Biotech Inc.
  • MORE
Metastatic Breast Cancer - Pipeline Review, H1 2016

Summary

‘Metastatic Breast Cancer - Pipeline Review, H1 2016’, provides an overview of the Metastatic Breast Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Breast Cancer and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
- The report reviews pipeline therapeutics for Metastatic Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Breast Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Breast Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Biocon Limited
  • Ensol Biosciences Inc.
  • Immunomedics, Inc.
  • Merck KGaA
  • Oncolytics Biotech Inc.
  • MORE
Introduction

Metastatic Breast Cancer Overview

Therapeutics Development

Metastatic Breast Cancer - Therapeutics under Development by Companies

Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes

Metastatic Breast Cancer - Pipeline Products Glance

Metastatic Breast Cancer - Products under Development by Companies

Metastatic Breast Cancer - Products under Investigation by Universities/Institutes

Metastatic Breast Cancer - Companies Involved in Therapeutics Development

Metastatic Breast Cancer - Therapeutics Assessment

Drug Profiles

Metastatic Breast Cancer - Recent Pipeline Updates

Metastatic Breast Cancer - Dormant Projects

Metastatic Breast Cancer - Discontinued Products

Metastatic Breast Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Metastatic Breast Cancer, H1 2016

Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Development by Companies, H1 2016 (Contd..6)

Number of Products under Development by Companies, H1 2016 (Contd..7)

Number of Products under Development by Companies, H1 2016 (Contd..8)

Number of Products under Development by Companies, H1 2016 (Contd..9)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Products under Development by Companies, H1 2016 (Contd..8)

Products under Development by Companies, H1 2016 (Contd..9)

Products under Development by Companies, H1 2016 (Contd..10)

Products under Development by Companies, H1 2016 (Contd..11)

Products under Development by Companies, H1 2016 (Contd..12)

Products under Development by Companies, H1 2016 (Contd..13)

Products under Development by Companies, H1 2016 (Contd..14)

Products under Investigation by Universities/Institutes, H1 2016

Metastatic Breast Cancer - Pipeline by AB Science SA, H1 2016

Metastatic Breast Cancer - Pipeline by AbbVie Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Advaxis, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016

Metastatic Breast Cancer - Pipeline by Alteogen Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2016

Metastatic Breast Cancer - Pipeline by Ambrx, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Amgen Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Aphios Corporation, H1 2016

Metastatic Breast Cancer - Pipeline by arGEN-X BV, H1 2016

Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Astellas Pharma Inc., H1 2016

Metastatic Breast Cancer - Pipeline by AstraZeneca Plc, H1 2016

Metastatic Breast Cancer - Pipeline by Bayer AG, H1 2016

Metastatic Breast Cancer - Pipeline by Beta Pharma, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Biocon Limited, H1 2016

Metastatic Breast Cancer - Pipeline by Bionovis SA, H1 2016

Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016

Metastatic Breast Cancer - Pipeline by Campus Technologies Freiburg GmbH, H1 2016

Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Celgene Corporation, H1 2016

Metastatic Breast Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Celltrion, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Clovis Oncology, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016

Metastatic Breast Cancer - Pipeline by Curadis GmbH, H1 2016

Metastatic Breast Cancer - Pipeline by Curaxys, S.L., H1 2016

Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Metastatic Breast Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016

Metastatic Breast Cancer - Pipeline by DexTech Medical AB, H1 2016

Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici S.p.A., H1 2016

Metastatic Breast Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016

Metastatic Breast Cancer - Pipeline by EirGenix Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Eisai Co., Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H1 2016

Metastatic Breast Cancer - Pipeline by Ensol Biosciences Inc., H1 2016

Metastatic Breast Cancer - Pipeline by EOS Biosciences, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Epigen Biosciences, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Etubics Corporation, H1 2016

Metastatic Breast Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Gene Techno Science Co., Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Genelux Corporation, H1 2016

Metastatic Breast Cancer - Pipeline by Genentech, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Gilead Sciences, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H1 2016

Metastatic Breast Cancer - Pipeline by GTx, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Hetero Drugs Limited, H1 2016

Metastatic Breast Cancer - Pipeline by Immune Design Corp., H1 2016

Metastatic Breast Cancer - Pipeline by Immunomedics, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Immupharma Plc, H1 2016

Metastatic Breast Cancer - Pipeline by Imugene Limited, H1 2016

Metastatic Breast Cancer - Pipeline by Incyte Corporation, H1 2016

Metastatic Breast Cancer - Pipeline by Intas Pharmaceuticals Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H1 2016

Metastatic Breast Cancer - Pipeline by Kadmon Corporation, LLC, H1 2016

Metastatic Breast Cancer - Pipeline by Kancera AB, H1 2016

Metastatic Breast Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2016

Metastatic Breast Cancer - Pipeline by Mabion SA, H1 2016

Metastatic Breast Cancer - Pipeline by MacroGenics, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by MandalMed, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Meabco A/S, H1 2016

Metastatic Breast Cancer - Pipeline by MedImmune, LLC, H1 2016

Metastatic Breast Cancer - Pipeline by Medivation, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Merck & Co., Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Merck KGaA, H1 2016

Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Merus B.V., H1 2016

Metastatic Breast Cancer - Pipeline by MetaStat, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Morphotek, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Mycenax Biotech Inc., H1 2016

Metastatic Breast Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by NantKwest, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Natco Pharma Limited, H1 2016

Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H1 2016

Metastatic Breast Cancer - Pipeline by NewLink Genetics Corporation, H1 2016

Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Novartis AG, H1 2016

Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2016

Metastatic Breast Cancer - Pipeline by OBI Pharma, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Oncobiologics, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016

Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Oncothyreon Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016

Metastatic Breast Cancer - Pipeline by Pfizer Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Pharma Mar, S.A., H1 2016

Metastatic Breast Cancer - Pipeline by PIQUR Therapeutics AG, H1 2016

Metastatic Breast Cancer - Pipeline by Plexxikon Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Polyphor Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Prescient Therapeutics Limited, H1 2016

Metastatic Breast Cancer - Pipeline by Prima BioMed Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Radius Health, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Samyang Holdings Corporation, H1 2016

Metastatic Breast Cancer - Pipeline by Sanofi, H1 2016

Metastatic Breast Cancer - Pipeline by Seattle Genetics, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Starpharma Holdings Limited, H1 2016

Metastatic Breast Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016

Metastatic Breast Cancer - Pipeline by Synthon Holdings BV, H1 2016

Metastatic Breast Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Transgene Biotek Limited, H1 2016

Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2016

Metastatic Breast Cancer - Pipeline by Verastem, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016

Metastatic Breast Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Wilex AG, H1 2016

Metastatic Breast Cancer - Pipeline by WntResearch AB, H1 2016

Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2016

Metastatic Breast Cancer - Pipeline by Zymeworks Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Metastatic Breast Cancer Therapeutics - Recent Pipeline Updates, H1 2016

Metastatic Breast Cancer - Dormant Projects, H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..1), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..2), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..3), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..4), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..5), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..6), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..7), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..8), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..9), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..10), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..11), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..12), H1 2016

Metastatic Breast Cancer - Dormant Projects (Contd..13), H1 2016

Metastatic Breast Cancer - Discontinued Products, H1 2016

Metastatic Breast Cancer - Discontinued Products (Contd..1), H1 2016

Metastatic Breast Cancer - Discontinued Products (Contd..2), H1 2016

Metastatic Breast Cancer - Discontinued Products (Contd..3), H1 2016

Metastatic Breast Cancer - Discontinued Products (Contd..4), H1 2016

List of Figures

Number of Products under Development for Metastatic Breast Cancer, H1 2016

Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
Acetylon Pharmaceuticals, Inc.
Adgero Biopharmaceuticals, Inc.
Advaxis, Inc.
Advenchen Laboratories, LLC
Alteogen Inc.
Amarna Therapeutics B.V.
Ambrx, Inc.
Amgen Inc.
Aphios Corporation
arGEN-X BV
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Beta Pharma, Inc.
Biocon Limited
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Campus Technologies Freiburg GmbH
CASI Pharmaceuticals Inc.
Celgene Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Celltrion, Inc.
Clovis Oncology, Inc.
Corcept Therapeutics Incorporated
Curadis GmbH
Curaxys, S.L.
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
DexTech Medical AB
Dompe Farmaceutici S.p.A.
Dr. Reddy's Laboratories Limited
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Ensol Biosciences Inc.
EOS Biosciences, Inc.
Epigen Biosciences, Inc.
Etubics Corporation
Eureka Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Gene Techno Science Co., Ltd.
Genelux Corporation
Genentech, Inc.
Genor BioPharma Co., Ltd.
Gilead Sciences, Inc.
Glycotope GmbH
GTx, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hetero Drugs Limited
Immune Design Corp.
Immunomedics, Inc.
Immupharma Plc
Imugene Limited
Incyte Corporation
Intas Pharmaceuticals Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Johnson & Johnson
Kadmon Corporation, LLC
Kancera AB
Karyopharm Therapeutics, Inc.
Laboratoires Pierre Fabre SA
Mabion SA
MacroGenics, Inc.
MandalMed, Inc.
Meabco A/S
MedImmune, LLC
Medivation, Inc.
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Merus B.V.
MetaStat, Inc.
Millennium Pharmaceuticals, Inc.
Morphotek, Inc.
Mycenax Biotech Inc.
NanoCarrier Co., Ltd.
NantKwest, Inc.
Natco Pharma Limited
Nektar Therapeutics
NewLink Genetics Corporation
Nippon Kayaku Co., Ltd.
Northwest Biotherapeutics, Inc.
Novartis AG
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Oncobiologics, Inc.
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Oncothyreon Inc.
Ono Pharmaceutical Co., Ltd.
Panacea Pharmaceuticals, Inc.
Paras Biopharmaceuticals Finland Oy
Pfizer Inc.
Pharma Mar, S.A.
PIQUR Therapeutics AG
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Polyphor Ltd.
Prescient Therapeutics Limited
Prima BioMed Ltd.
Puma Biotechnology, Inc.
Radius Health, Inc.
Samyang Holdings Corporation
Sanofi
Seattle Genetics, Inc.
Shanghai Henlius Biotech Co., Ltd.
Starpharma Holdings Limited
Sun Pharma Advanced Research Company Ltd.
Syndax Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Synthon Holdings BV
Taiho Pharmaceutical Co., Ltd.
TRACON Pharmaceuticals, Inc.
Transgene Biotek Limited
Vaxil Bio Therapeutics Ltd.
Verastem, Inc.
Vertex Pharmaceuticals Incorporated
VioQuest Pharmaceuticals, Inc.
Wilex AG
WntResearch AB
ZIOPHARM Oncology, Inc.
Zymeworks Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll